Biomarker Profiling of Neurovascular Diseases in Patients with Stage 5 Chronic Kidney Disease (scientific article published on 22 October 2018)

Guidelines for carotid endarterectomy: a statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association

Q28263859

CD40 ligand as a potential biomarker for atherosclerotic instability

Q28288474

Inflammatory markers in patients with internal carotid artery stenosis.

Q30454669

Assessment of Blood-Brain Barrier Disruption in Stroke

Q31004800

Cognitive Impairment in Chronic Kidney Disease: Vascular Milieu and the Potential Therapeutic Role of Exercise

Q33630922

Stroke in chronic kidney disease

Q33752170

Age-related diagnostic value of D-dimer testing and the role of inflammation in patients with suspected deep vein thrombosis.

Q33870617

Symptomatic Carotid Artery Stenosis: Surgery, Stenting, or Medical Therapy?

Q33871078

Platelet transfusions: Impact on hemostasis, thrombosis, inflammation and clinical outcomes

Q34708937

Review on uremic toxins: classification, concentration, and interindividual variability

Q35098883

Disruption in the Blood-Brain Barrier: The Missing Link between Brain and Body Inflammation in Bipolar Disorder?

Q35649716

Vascular calcification burden of Chinese patients with chronic kidney disease: methodology of a cohort study

Q35735968

Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice

Q35995921

Risk of Stroke in Patients with ESRD

Q36025660

Procalcitonin-guided diagnosis and antibiotic stewardship revisited

Q36257991

Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment

Q37734702

Racial-ethnic disparities in stroke care: the American experience: a statement for healthcare professionals from the American Heart Association/American Stroke Association

Q37880516

Analytical characteristics of high-sensitivity cardiac troponin assays

Q37941605

Stroke and cerebrovascular diseases in patients with chronic kidney disease

Q38230258

Procalcitonin: potential role in diagnosis and management of sepsis

Q38413771

Status epilepticus, blood-brain barrier disruption, inflammation, and epileptogenesis

Q38469526

Kidney-brain axis inflammatory cross-talk: from bench to bedside

Q38682647

Targeting cell adhesion molecules with nanoparticles using in vivo and flow-based in vitro models of atherosclerosis

Q38757789

Oxalate, inflammasome, and progression of kidney disease

Q38837256

Angiopoietin-1 and Angiopoietin-2 in metabolic disorders: therapeutic strategies to restore the highs and lows of angiogenesis in diabetes.

Q38877104

Race, sex and occlusive cerebrovascular disease: a review

Q39740153

High-Grade Inflammation in Renal Failure Patients, According to Mean Platelet Volume, Improves at the End of Two Years After Transplantation

Q41149186

Unfractionated heparin but not enoxaparin causes delayed plasma PAI-1 depletion in hemodialysis patients: a prospective study

Q46981992

Effect of high- and low-molecular-weight heparins on thrombin-thrombomodulin interaction and protein C activation

Q47280861

Bacterial lipopolysaccharide-induced systemic inflammation alters perfusion of white matter-rich regions without altering flow in brain-irrigating arteries: Relationship to blood-brain barrier breakdown?

Q47781969

Neurocognitive disorders in DSM-5.

Q50706767

Role of plasminogen activator inhibitor-1 in coronary pathophysiology.

Q52679390

Expression of the NLRP3 Inflammasome in Carotid Atherosclerosis.

Q53346950

Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation.

Q55496554

Effects of older age on fibrin D-dimer, C-reactive protein, and other hemostatic and inflammatory variables in men aged 60-79 years

Q57416334

Ethnicity and stroke : beware of the fallacies